Alumis Inc and Acelyrin, Inc.
Type: Merger agreement
Merged companies: Alumis Inc., Acelyrin Inc.
Focus: Immune-mediated diseases
Stockholders percentage: Alumis (52%), Acelyrin (48%)
Financial impact: The merger creates a clinical-stage biopharmaceutical company with a diversified immunology pipeline, enhanced financial stability, and increased capacity to develop innovative therapies for immune-mediated diseases.
Alumis Inc., a clinical-stage biopharmaceutical company leveraging precision medicine to improve outcomes for patients with immune-mediated diseases, and Acelyrin, Inc., a late-stage clinical biopharma company focused on rapidly advancing transformative therapies in immunology, have announced a revision to the terms of their previously disclosed merger agreement.
Under the amended terms, Acelyrin stockholders will now receive 0.4814 shares of Alumis common stock for each share of Acelyrin common stock held. This revised exchange ratio reflects a notable increase in Acelyrin stockholders' stake in the combined entity compared to the original agreement.
Following the amendment, Alumis stockholders will own approximately 52% and Acelyrin stockholders approximately 48% of the combined company on a fully diluted basis, signaling a more balanced distribution of ownership and a unified focus on advancing innovation in immunology.
Alumis, Acelyrin Merge to Forge Immunology Leader
Alumis Inc., established in 2021, and Acelyrin, Inc., founded in July 2020, are both clinical-stage biopharmaceutical companies and currently do not have any approved or marketed therapies. The merger of Alumis Inc. and Acelyrin, Inc. marks a strategic step toward establishing a premier clinical-stage biopharmaceutical company dedicated to the development of innovative treatments for immune-mediated diseases. The newly combined entity will be well-positioned to capitalize on a robust and diversified pipeline, enhanced financial flexibility, and expanded capabilities to bring transformative therapies to patients in need.
This transaction is designed not only to strengthen both organizations' scientific and clinical platforms but also to unlock meaningful value for Acelyrin shareholders through increased ownership in a more financially stable and growth-oriented company.
“The Alumis–Acelyrin merger creates a stronger clinical-stage biopharma company with a diversified immunology pipeline, enhanced financial flexibility, and a focused mission to deliver innovative treatments for immune-mediated diseases.”
Key Strategic Benefits
- Robust and Complementary Pipeline: The merger unites Alumis's ESK-001, a promising TYK2 inhibitor, with Acelyrin’s lonigutamab, an anti-IGF-1R monoclonal antibody. This combination significantly broadens the development pipeline, offering multiple shots on goal across various indications in immunology.
- Stronger Financial Position: With enhanced capital resources, the combined company will be better equipped to fund ongoing R&D efforts, support multiple upcoming clinical trial data readouts, and invest in long-term commercial infrastructure.
- Extended Operational Runway: The increased liquidity and capital efficiency resulting from the merger will provide the combined entity with a longer financial runway, helping to sustain innovation while pursuing market entry strategies.
- Diversified Therapeutic Portfolio: By combining assets across different mechanisms of action and disease targets, the company will reduce dependency on any single program and improve its ability to adapt to market dynamics.
- Focused Mission in Immunology: The unified company will focus sharply on immune-mediated conditions—an area with significant unmet medical needs and long-term growth potential.